PFSCF News Alert Prometic Life Scienc (PFSCF) 1.5900 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 26, 2014 at 11:06 AM

Prometic Life Scienc (PFSCF) 1.5900 $PFSCF

ProMetic to Be Added to S&P/TSX SmallCap Index
Marketwire - Tue Sep 16, 6:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it will be added to the S&P/TSX SmallCap Index ("Index"

, effective after the close of trading on Friday, September 19, 2014, as the result of the annual review of the Index.

Chemotherapy Induced Anemia Therapeutics Pipeline Review 2014 - 9 Companies & 11 Drug Profiles
M2 - Wed Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqbww2/chemotherapy) has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - 3SBio Inc. - ProMetic Life Sciences Inc. - Avesthagen Limited - Therapure Biopharma Inc. - Tarix Pharmaceuticals LTD. - Aprogen, Inc. - Tolero Pharmaceuticals, Inc. - SBI Pharmaceuticals Co., Ltd. Drug Profiles - epoetin alfa - PBI-1402 - LY-2787106 - aminolevulinic acid hydrochloride - NuPIAO - darbepoetin alfa - PanCyte - PBI-4494 - TBI-304 - darbepoetin alfa - TP-0413 For more information visit http://www.researchandmarkets.com/research/tq...emotherapy

Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ProMetic Reports Successful PBI-4050 Pre-IND Meeting with the FDA
Marketwire - Wed Sep 03, 5:31AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA"

for its anti-fibrotic, lead drug candidate, PBI-4050.

ProMetic Reports its Second Quarter 2014 Highlights and Financial Results
Marketwire - Thu Aug 14, 3:02PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

today reported revenues of $4.4 million and a net profit of $23.4 million for the second quarter ended June 30, 2014 resulting from the recognition of a gain on revaluation of the equity investment of ProMetic's equity interest in NantPro.

ProMetic to Report its Second Quarter 2014 Financial Results and Hold Conference Call / Webcast
Marketwire - Mon Aug 11, 11:35AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"

today announced that it will report its financial results for the second quarter ended June 30, 2014 on Thursday August 14, 2014 after market hours.

ProMetic Secures $20 Million Follow-on Investment from Thomvest Seed Capital Inc.
Marketwire - Fri Aug 01, 7:18AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it has secured a follow-on investment from Thomvest Seed Capital Inc. ("Thomvest"

, the Toronto-based investment vehicle of Peter J. Thomson, consisting of a $20 million Loan. As partial consideration for the Loan, ProMetic has granted Thomvest 16,723,807 warrants with an exercise price of $1.87 per common share, a premium of 52% to yesterday's closing share price.

ProMetic Enters Into New Product Program With an Existing Multinational Client
Marketwire - Thu Jul 24, 7:40AM CDT
July 24, 2014 - ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today the signing of an agreement (the "Agreement"

by ProMetic's UK subsidiary, ProMetic Biosciences Ltd ("PBL"

, with one of its existing multinational clients, a global leader in the biotherapeutics industry.

ProMetic to Commercially Launch Fibrinogen in the Fourth Quarter of 2014
Marketwire - Thu Jul 10, 7:09AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today that it will launch fibrinogen for commercial sales during the fourth quarter of 2014 after its successful scale-up at its Laval based plasma purification facility, ProMetic BioProduction Inc. ("PBP"

. This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin.

ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial
Marketwire - Wed Jun 18, 5:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"

reported today that it has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers. ProMetic's PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested.

ProMetic Reports Successful Pre-IND Meeting with the FDA
Marketwire - Wed Apr 02, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA"

for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Opens New Café in Novato, CA

Another Feather in Paris Baguette’s Cap Alright, as far as pastry shops go, Paris Baguette is rolling out those cinnamon rolls like they're planting flags on the moon. They've just added a new café in Novato, California, bringing the artisanal charm of their iconic baked goods to yet another American doorstep. A Local Affair with Big Aspirations The man of the hour,...

BULL Faces Class Action After Regulatory Fines

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

Retirement Dreams Dashed: 61% Withdraw Early

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

$10,000 Boost Fuels Nichols College's Archaeological Quest

Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...

IM Cannabis's Third Quarter Financial Jolt

By Caleb Price Updated Nov 13, 2026 Category News Views 120

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Odessa Water Overbilling Lawsuit Surges Ahead

Full Steam Ahead for Odessa's Water Fight Odessa, a dust-blown Texas town, ain't giving up without a fight. The court just lit a fire under the efforts of 46,000 residents and businesses hollering about their water bills that seemed to skyrocket outta nowhere. This court ruling lets the class action against the City of Odessa and Performance Services—they're the folks...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Pine AI Unveils AI Studio & Real-World Call Feature

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...